Cancer Gene Therapy (Prostate)

Preclinical Model Demonstrates Safety of Suicide Gene Therapy

Published in Cancer Weekly, May 18th, 1998

A preclinical murine model has demonstrated the safety of herpes simplex virus thymidine kinase/ganciclovir (HSVtk/GSV) suicide gene therapy for prostate cancer.

Terry L. Timme and a team of researchers from numerous institutions evaluated the safety and potential toxicity of an adenoviral (ADV) vector containing the HSVtk gene in a clinically relevant murine model ("Local Inflammatory Response and Vector Spread after Direct Intraprostatic Injection of a Recombinant Adenovirus Containing the Herpes Simplex Virus Thymidine Kinase Gene and Ganciclovir Therapy in Mice," Cancer Gene Therapy, March/April 1998;5(2):74-82).

"In support of our ongoing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry